Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study

Trial Profile

Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Asparaginase; Busulfan; Ciclosporin; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Methotrexate; Mitoxantrone
  • Indications Acute myeloid leukaemia; Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Apr 2017 Results assessing CNA presence and its prognostic significance on survival in 460 AML patients from three studies (NCT00003790, NCT00070174, and NCT01407757) published in the Blood
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2015 Results from this and other trial (see trial profile- 700016709) and presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top